Teriparatide (Azelon Pharmaceuticals)

N/A

Report date: 2022/11/25 17:31:12

Base Information

Drug NameTeriparatide (Azelon Pharmaceuticals)
Drug Alias NamePTH 1-34 - AzelonTeriparatide injection - Azelon PharmaceuticalsTeriparatide intranasal - Azelon PharmaceuticalsParathyroid-hormone-1-34 - Azelon PharmaceuticalsZT-034
ClassificationBiologics > Protein drugs > Recombinant polypeptide
Mechanisms of ActionOsteogenesis stimulants
TargetsParathyroid hormone receptor
Therapy Area/IndicationsOsteoporosisBone Diseases, Metabolic
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesAzelon Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAzelon Pharmaceuticals Inc
Active IndicationsN/A
Inactive IndicationsOsteoporosisBone Diseases, Metabolic

Other Information

ATC CodeN/A